SMScott M. MacKenzie

Scott M. MacKenzie

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Scott M. MacKenzie has a total of 413 co-authors. Here are the top co-authors by number of shared publications:

  • Robert Fraser

    Institute of Cardiovascular and Medical Science, University of Glasgow, Glasgow, UK

    19 shared publications
  • Eleanor Davies

    School of Cardiovascular and Metabolic Health, BHF Glasgow Cardiovascular Research Centre, University of Glasgow, Glasgow, United Kingdom

    18 shared publications
  • Eleanor Davies

    British Heart Foundation Glasgow Cardiovascular Research Centre (BHF GCRC), Institute of Cardiovascular & Medical Sciences (ICAMS), University of Glasgow, Glasgow G12 8TA, UK

    9 shared publications
  • John M. C. Connell

    BHF Glasgow Cardiovascular Research Centre, University of Glasgow, 126 University Place, Glasgow G12 8TA, United Kingdom

    6 shared publications
  • Samantha Alvarez-Madrazo

    Institute of Cardiovascular and Medical Science, University of Glasgow, Glasgow, UK

    6 shared publications
  • John M. Connell

    Ninewells Hospital and Medical School, University of Dundee, Dundee, UK

    5 shared publications

Latest Publications

  • Open Access

    Identification of hypertension subtypes using microRNA profiles and machine learning

    by Smarti Reel, Parminder S Reel, Josie Van Kralingen, Casper K Larsen, Stacy Robertson, Scott M MacKenzie, Alexandra Riddell, John D McClure, Stelios Lamprou, John M C Connell, et al.

    Objective: Hypertension is a major cardiovascular risk factor affecting about 1 in 3 adults. Although the majority of hypertension cases (∼90%) are classified as “primary hypertension” (PHT), endocrine hypertension (EHT) accounts for ∼10% of cases and is caused by underlying conditions such as primary aldosteronism (PA), Cushing's syndrome (CS), pheochromocytoma or paraganglioma (PPGL). EHT is often misdiagnosed as PHT leading to delays in treatment for the underlying condition, reduced quality of life and costly, often ineffective, antihypertensive treatment. MicroRNA (miRNA) circulating in the plasma is emerging as an attractive potential biomarker for various clinical conditions due to its ease of sampling, the accuracy of its measurement and the correlation of particular disease states with circulating levels of specific miRNAs. Methods: This study systematically presents the most discriminating circulating miRNA features responsible for classifying and distinguishing EHT and its subtypes (PA, PPGL, and CS) from PHT using 8 different supervised machine learning (ML) methods for the prediction. Results: The trained models successfully classified PPGL, CS, and EHT from PHT with area under the curve (AUC) of 0.9 and PA from PHT with AUC 0.8 from the test set. The most prominent circulating miRNA features for hypertension identification of different disease combinations were hsa-miR-15a-5p and hsa-miR-32-5p. Conclusions: This study confirms the potential of circulating miRNAs to serve as diagnostic biomarkers for EHT and the viability of ML as a tool for identifying the most informative miRNA species.


  • MicroRNAs in aldosterone production and action

    by Scott M. MacKenzie, Lara A. Birch, Stelios Lamprou, Parisa Rezvanisanijouybari, May Fayad, Maria-Christina Zennaro, Eleanor Davies


  • Open Access

    Circulating microRNAs as Diagnostic Markers in Primary Aldosteronism

    by Scott M. MacKenzie, Hannah Saunders, Josie C. van Kralingen, Stacy Robertson, Alexandra Riddell, Maria-Christina Zennaro, Eleanor Davies

    Primary aldosteronism (PA) is a common and highly treatable condition, usually resulting from adrenocortical tumorous growth or hyperplasia. PA is currently underdiagnosed owing to its complex and protracted diagnostic procedures. A simplified biomarker-based test would be highly valuable in reducing cardiovascular morbidity and mortality. Circulating microRNAs are emerging as potential biomarkers for a number of conditions due to their stability and accessibility. PA is known to alter microRNA expression in adrenocortical tissue; if these changes or their effects are mirrored in the circulating miRNA profile, then this could be exploited by a diagnostic test. However, the reproducibility of studies to identify biomarker-circulating microRNAs has proved difficult for other conditions due to a series of technical challenges. Therefore, any studies seeking to definitively identify circulating microRNA biomarkers of PA must address this in their design. To this end, we are currently conducting the circulating microRNA arm of the ongoing ENS@T-HT study. In this review article, we present evidence to support the utility of circulating microRNAs as PA biomarkers, describe the practical challenges to this approach and, using ENS@T-HT as an example, discuss how these might be overcome.


  • Aldosterone

    by Scott M. MacKenzie, Aurelie Nguyen Dinh Cat, Josie C. van Kralingen, Eleanor Davies


  • Open Access

    Runx1 Deficiency Protects Against Adverse Cardiac Remodeling After Myocardial Infarction

    by Charlotte S. McCarroll, Weihong He, Kirsty Foote, Ashley Bradley, Karen Mcglynn, Francesca Vidler, Colin Nixon, Katrin Nather, Caroline Fattah, Alexandra Riddell, et al.

    Background: Myocardial infarction (MI) is a leading cause of heart failure and death worldwide. Preservation of contractile function and protection against adverse changes in ventricular architecture (cardiac remodeling) are key factors to limiting progression of this condition to heart failure. Consequently, new therapeutic targets are urgently required to achieve this aim. Expression of the Runx1 transcription factor is increased in adult cardiomyocytes after MI; however, the functional role of Runx1 in the heart is unknown. Methods: To address this question, we have generated a novel tamoxifen-inducible cardiomyocyte-specific Runx1 -deficient mouse. Mice were subjected to MI by means of coronary artery ligation. Cardiac remodeling and contractile function were assessed extensively at the whole-heart, cardiomyocyte, and molecular levels. Results: Runx1 -deficient mice were protected against adverse cardiac remodeling after MI, maintaining ventricular wall thickness and contractile function. Furthermore, these mice lacked eccentric hypertrophy, and their cardiomyocytes exhibited markedly improved calcium handling. At the mechanistic level, these effects were achieved through increased phosphorylation of phospholamban by protein kinase A and relief of sarco/endoplasmic reticulum Ca 2+ -ATPase inhibition. Enhanced sarco/endoplasmic reticulum Ca 2+ -ATPase activity in Runx1-deficient mice increased sarcoplasmic reticulum calcium content and sarcoplasmic reticulum–mediated calcium release, preserving cardiomyocyte contraction after MI. Conclusions: Our data identified Runx1 as a novel therapeutic target with translational potential to counteract the effects of adverse cardiac remodeling, thereby improving survival and quality of life among patients with MI.


  • Open Access

    Regulation of Corticosteroidogenic Genes by MicroRNAs

    by Stacy Robertson, Louise A. Diver, Samantha Alvarez-Madrazo, Craig Livie, Ayesha Ejaz, Robert Fraser, John M. Connell, Scott M. MacKenzie, Eleanor Davies

    The loss of normal regulation of corticosteroid secretion is important in the development of cardiovascular disease. We previously showed that microRNAs regulate the terminal stages of corticosteroid biosynthesis. Here, we assess microRNA regulation across the whole corticosteroid pathway. Knockdown of microRNA using Dicer1 siRNA in H295R adrenocortical cells increased levels of CYP11A1, CYP21A1, and CYP17A1 mRNA and the secretion of cortisol, corticosterone, 11-deoxycorticosterone, 18-hydroxycorticosterone, and aldosterone. Bioinformatic analysis of genes involved in corticosteroid biosynthesis or metabolism identified many putative microRNA-binding sites, and some were selected for further study. Manipulation of individual microRNA levels demonstrated a direct effect of miR-125a-5p and miR-125b-5p on CYP11B2 and of miR-320a-3p levels on CYP11A1 and CYP17A1 mRNA. Finally, comparison of microRNA expression profiles from human aldosterone-producing adenoma and normal adrenal tissue showed levels of various microRNAs, including miR-125a-5p to be significantly different. This study demonstrates that corticosteroidogenesis is regulated at multiple points by several microRNAs and that certain of these microRNAs are differentially expressed in tumorous adrenal tissue, which may contribute to dysregulation of corticosteroid secretion. These findings provide new insights into the regulation of corticosteroid production and have implications for understanding the pathology of disease states where abnormal hormone secretion is a feature.


  • Circulating levels of miR24-1 cluster microRNAs are increased in primary aldosteronism

    by Kralingen Josie van, Cali Anderson, E. Marie Freel, John M. Connell, Scott M. MacKenzie, Eleanor Davies

    Introduction: Measurement of microRNA (miRNA) in aldosterone-producing adenoma (APA) tissue from primary aldosteronism (PA) patients show levels of the miR24-1 cluster miRNAs (i.e. miRNAs 24-1, 27b and 23b) are significantly reduced relative to normal adrenal tissue. Our previous studies also show that miRNA-24 directly targets CYP11B2 (aldosterone synthase) gene expression. Circulating miRNAs released into the bloodstream may be diagnostic biomarkers or signalling molecules. Here, we assessed whether circulating levels of miR24-1 cluster miRNAs differ significantly between PA patients and essential hypertensives, and whether they correlate with relevant phenotypic traits. Methods: Patients with essential hypertension patients (n=18) were drawn from the British Genetics of Hypertension (BRIGHT) study and matched with 18 confirmed PA patients for age, gender and systolic blood pressure. Circulating miRNA was isolated from 200 μL EDTA plasma and analysed using quantitative realtime assays for miRNAs 24, 27b and 23b. Results: PA patients had significantly increased circulating levels of miRNAs 24 (PPPPPPCYP11B2 expression when aldosterone levels are high. Therefore, increased secretion of these miRNAs into the circulation may be the result of high aldosterone levels and be intended to suppress its release. Future studies will examine the role of these miRNAs in the aetiology and pathology of PA.

  • Open Access

    ACTH and Polymorphisms at Steroidogenic Loci as Determinants of Aldosterone Secretion and Blood Pressure

    by Scott M. MacKenzie, E. Marie Freel, John M. Connell, Robert Fraser, Eleanor Davies

    The majority of genes contributing to the heritable component of blood pressure remain unidentified, but there is substantial evidence to suggest that common polymorphisms at loci involved in the biosynthesis of the corticosteroids aldosterone and cortisol are important. This view is supported by data from genome-wide association studies that consistently link the CYP17A1 locus to blood pressure. In this review article, we describe common polymorphisms at three steroidogenic loci (CYP11B2, CYP11B1 and CYP17A1) that alter gene transcription efficiency and levels of key steroids, including aldosterone. However, the mechanism by which this occurs remains unclear. While the renin angiotensin system is rightly regarded as the major driver of aldosterone secretion, there is increasing evidence that the contribution of corticotropin (ACTH) is also significant. In light of this, we propose that the differential response of variant CYP11B2, CYP11B1 and CYP17A1 genes to ACTH is an important determinant of blood pressure, tending to predispose individuals with an unfavourable genotype to hypertension.


  • Analysis of the Aldosterone Synthase (CYP11B2) and 11β-Hydroxylase (CYP11B1) Genes

    by Scott M. MacKenzie, Eleanor Davies, Samantha Alvarez-Madrazo

    The aldosterone synthase (CYP11B2) and 11β-hydroxylase (CYP11B1) enzymes are known to be important players in the development of hypertension. Sequencing of the CYP11B2 and CYP11B1 genes and quantification of their respective mRNAs is greatly complicated by their high degree of sequence similarity. The need to ensure gene specificity during such analysis has required the development of particular methods for the detection of key polymorphisms at these loci, which are detailed in this chapter.


  • Genome-wide associations for birth weight and correlations with adult disease

    by CHARGE Consortium Hematology Working Group, Momoko Horikoshi, Early Growth Genetics (EGG) Consortium, Robin N. Beaumont, Felix R. Day, Nicole M. Warrington, Marjolein N. Kooijman, Juan Fernandez-Tajes, Bjarke Feenstra, Natalie R. van Zuydam, et al.

    Multi-ancestry genome-wide association analyses for birth weight in 153,781 individuals identified 60 genomic loci in which birth weight and fetal genotype were associated and found an inverse genetic correlation between birth weight and cardiometabolic risk. Mark McCarthy and colleagues from the Early Growth Genetics (EGG) Consortium report multi-ancestry genome-wide association analyses for birth weight in 153,781 individuals, identifying 60 genomic loci where the fetal genotype was associated with birth weight. They demonstrate an inverse genetic correlation between birth weight and developing type 2 diabetes or coronary artery disease as an adult, suggesting that previous epidemiological associations may be explained in part by shared genetic variation influencing both early growth and adult disease. Birth weight (BW) has been shown to be influenced by both fetal and maternal factors and in observational studies is reproducibly associated with future risk of adult metabolic diseases including type 2 diabetes (T2D) and cardiovascular disease1. These life-course associations have often been attributed to the impact of an adverse early life environment. Here, we performed a multi-ancestry genome-wide association study (GWAS) meta-analysis of BW in 153,781 individuals, identifying 60 loci where fetal genotype was associated with BW (P < 5 × 10−8). Overall, approximately 15% of variance in BW was captured by assays of fetal genetic variation. Using genetic association alone, we found strong inverse genetic correlations between BW and systolic blood pressure (Rg = −0.22, P = 5.5 × 10−13), T2D (Rg = −0.27, P = 1.1 × 10−6) and coronary artery disease (Rg = −0.30, P = 6.5 × 10−9). In addition, using large -cohort datasets, we demonstrated that genetic factors were the major contributor to the negative covariance between BW and future cardiometabolic risk. Pathway analyses indicated that the protein products of genes within BW-associated regions were enriched for diverse processes including insulin signalling, glucose homeostasis, glycogen biosynthesis and chromatin remodelling. There was also enrichment of associations with BW in known imprinted regions (P = 1.9 × 10−4). We demonstrate that life-course associations between early growth phenotypes and adult cardiometabolic disease are in part the result of shared genetic effects and identify some of the pathways through which these causal genetic effects are mediated.